{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:25:10Z","timestamp":1776230710853,"version":"3.50.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s11864-019-0639-0","type":"journal-article","created":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T10:06:11Z","timestamp":1556877971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?"],"prefix":"10.1007","volume":"20","author":[{"given":"Nieves","family":"Martinez Chanza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren C.","family":"Harshman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,3]]},"reference":[{"key":"639_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"639_CR2","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"639_CR3","doi-asserted-by":"publisher","first-page":"804","DOI":"10.6004\/jnccn.2017.0100","volume":"15","author":"RJ Motzer","year":"2017","unstructured":"Motzer RJ, Jonasch E, Agarwal N, et al. Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15:804\u201334.","journal-title":"J Natl Compr Cancer Netw"},{"key":"639_CR4","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.eururo.2018.01.005","volume":"73","author":"BC Leibovich","year":"2018","unstructured":"Leibovich BC, Lohse CM, Cheville JC, et al. Predicting oncologic outcomes in renal cell carcinoma after surgery. Eur Urol. 2018;73:772\u201380.","journal-title":"Eur Urol"},{"key":"639_CR5","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859\u201366.","journal-title":"N Engl J Med"},{"key":"639_CR6","doi-asserted-by":"publisher","first-page":"5506","DOI":"10.1200\/JCO.2007.14.1226","volume":"25","author":"KM Pisters","year":"2007","unstructured":"Pisters KM, Evans WK, Azzoli CG, et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol. 2007;25:5506\u201318.","journal-title":"J Clin Oncol"},{"key":"639_CR7","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"C Davies","year":"2011","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative G, Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771\u201384.","journal-title":"Lancet"},{"key":"639_CR8","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1200\/JCO.2015.63.4238","volume":"33","author":"T Andre","year":"2015","unstructured":"Andre T, de Gramont A, Vernerey D, et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol. 2015;33:4176\u201387.","journal-title":"J Clin Oncol"},{"key":"639_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0140-6736(08)60697-2","volume":"372","author":"C Wood","year":"2008","unstructured":"Wood C, Srivastava P, Bukowski R, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet. 2008;372:145\u201354.","journal-title":"Lancet"},{"key":"639_CR10","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1200\/JCO.2001.19.2.425","volume":"19","author":"G Pizzocaro","year":"2001","unstructured":"Pizzocaro G, Piva L, Colavita M, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol. 2001;19:425\u201331.","journal-title":"J Clin Oncol"},{"key":"639_CR11","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1200\/JCO.2003.02.005","volume":"21","author":"EM Messing","year":"2003","unstructured":"Messing EM, Manola J, Wilding G, et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group\/Intergroup trial. J Clin Oncol. 2003;21:1214\u201322.","journal-title":"J Clin Oncol"},{"key":"639_CR12","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s10147-011-0345-9","volume":"18","author":"S Hinotsu","year":"2013","unstructured":"Hinotsu S, Kawai K, Ozono S, et al. Randomized controlled study of natural interferon alpha as adjuvant treatment for stage II or III renal cell carcinoma. Int J Clin Oncol. 2013;18:68\u201374.","journal-title":"Int J Clin Oncol"},{"key":"639_CR13","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1200\/JCO.2003.02.014","volume":"21","author":"JI Clark","year":"2003","unstructured":"Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol. 2003;21:3133\u201340.","journal-title":"J Clin Oncol"},{"key":"639_CR14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejca.2013.08.019","volume":"50","author":"M Aitchison","year":"2014","unstructured":"Aitchison M, Bray CA, Van Poppel H, et al. Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)\/National Cancer Research Institute trial. Eur J Cancer. 2014;50:70\u20137.","journal-title":"Eur J Cancer"},{"key":"639_CR15","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/CJI.0000000000000055","volume":"37","author":"R Passalacqua","year":"2014","unstructured":"Passalacqua R, Caminiti C, Buti S, et al. Adjuvant low-dose interleukin-2 (IL-2) plus interferon-alpha (IFN-alpha) in operable renal cell carcinoma (RCC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC). J Immunother. 2014;37:440\u20137.","journal-title":"J Immunother"},{"key":"639_CR16","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/sj.bjc.6602443","volume":"92","author":"J Atzpodien","year":"2005","unstructured":"Atzpodien J, Schmitt E, Gertenbach U, et al. Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer. 2005;92:843\u20136.","journal-title":"Br J Cancer"},{"key":"639_CR17","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0022-5347(17)43647-0","volume":"138","author":"G Pizzocaro","year":"1987","unstructured":"Pizzocaro G, Piva L, Di Fronzo G, et al. Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J Urol. 1987;138:1379\u201381.","journal-title":"J Urol"},{"issue":"5","key":"639_CR18","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/cncr.31154","volume":"124","author":"LC Harshman","year":"2018","unstructured":"Harshman LC, Xie W, Moreira RB, et al. Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: a trial-level meta-analysis. Cancer. 2018;124(5):925\u201333.","journal-title":"Cancer."},{"key":"639_CR19","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMra1601333","volume":"376","author":"TK Choueiri","year":"2017","unstructured":"Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376:354\u201366.","journal-title":"N Engl J Med"},{"key":"639_CR20","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(16)00559-6","volume":"387","author":"NB Haas","year":"2016","unstructured":"\u2022\u2022 Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016;387:2008\u201316 Largest phase III trial evaluating adjuvant sunitinib or sorafenib versus placebo in patients with RCC at risk of recurrence after nephrectomy but failed to demostrate a disease free or overall survival benefit.","journal-title":"Lancet"},{"key":"639_CR21","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1056\/NEJMoa1611406","volume":"375","author":"A Ravaud","year":"2016","unstructured":"\u2022\u2022 Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016;375:2246\u201354. Phase III trial evaluating sunitinib versus placebo in high risk clear cell adjuvant renal cell carcinoma which contrary to ASSURE did show a significant increase in disease free survival but has not shown an improvement in overall survival.","journal-title":"N Engl J Med"},{"key":"639_CR22","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1200\/JCO.2017.73.5324","volume":"35","author":"RJ Motzer","year":"2017","unstructured":"\u2022\u2022 Motzer RJ, Haas NB, Donskov F, et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol. 2017;35:3916\u201323 PROTECT was a phase III trial comparing adjuvant pazopanib versus placebo in renal cell carcinoma patients who had undergone nephrectomy and did not find a difference in disease free or overall survival at the 600mg dose.","journal-title":"J Clin Oncol"},{"key":"639_CR23","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1093\/annonc\/mdy454","volume":"29","author":"M Gross-Goupil","year":"2018","unstructured":"\u2022\u2022 Gross-Goupil M, Kwon TG, Eto M, et al. Axitinib versus placebo as an adjuvant treatment for renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol. 2018;29:2371\u20138. Recently reported phase III trial evaluating adjuvant axitinib versus placebo in patients with locoregional renal cell carcinoma at risk of recurrence after nephrectomy which did not demonstrate a significant difference in disease free survival.","journal-title":"Ann Oncol"},{"key":"639_CR24","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803\u201313.","journal-title":"N Engl J Med"},{"key":"639_CR25","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277\u201390.","journal-title":"N Engl J Med"},{"key":"639_CR26","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1016\/j.juro.2011.02.059","volume":"185","author":"SP Kim","year":"2011","unstructured":"Kim SP, Alt AL, Weight CJ, et al. Independent validation of the 2010 American Joint Committee on Cancer TNM classification for renal cell carcinoma: results from a large, single institution cohort. J Urol. 2011;185:2035\u20139.","journal-title":"J Urol"},{"key":"639_CR27","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1200\/JCO.2004.09.104","volume":"22","author":"JJ Patard","year":"2004","unstructured":"Patard JJ, Kim HL, Lam JS, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004;22:3316\u201322.","journal-title":"J Clin Oncol"},{"key":"639_CR28","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/cncr.11234","volume":"97","author":"BC Leibovich","year":"2003","unstructured":"Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97:1663\u201371.","journal-title":"Cancer"},{"key":"639_CR29","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1016\/S0022-5347(05)64153-5","volume":"168","author":"I Frank","year":"2002","unstructured":"Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168:2395\u2013400.","journal-title":"J Urol"},{"key":"639_CR30","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0022-5347(05)66077-6","volume":"166","author":"MW Kattan","year":"2001","unstructured":"Kattan MW, Reuter V, Motzer RJ, et al. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166:63\u20137.","journal-title":"J Urol"},{"key":"639_CR31","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/j.1464-410X.2003.04505.x","volume":"92","author":"L Cindolo","year":"2003","unstructured":"Cindolo L, de la Taille A, Messina G, et al. A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int. 2003;92:901\u20135.","journal-title":"BJU Int"},{"key":"639_CR32","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1016\/j.juro.2008.01.101","volume":"179","author":"GV Raj","year":"2008","unstructured":"Raj GV, Thompson RH, Leibovich BC, Blute ML, Russo P, Kattan MW. Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol. 2008;179:2146\u201351.","journal-title":"J Urol"},{"key":"639_CR33","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1200\/JCO.2006.06.1218","volume":"25","author":"PI Karakiewicz","year":"2007","unstructured":"Karakiewicz PI, Briganti A, Chun FK, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol. 2007;25:1316\u201330.","journal-title":"J Clin Oncol"},{"key":"639_CR34","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1200\/JCO.2001.19.6.1649","volume":"19","author":"A Zisman","year":"2001","unstructured":"Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19:1649\u201357.","journal-title":"J Clin Oncol"},{"issue":"8","key":"639_CR35","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1634\/theoncologist.2014-0105","volume":"19","author":"SK Pal","year":"2014","unstructured":"Pal SK, Haas NB. Adjuvant therapy for renal cell carcinoma: past, present, and future. Oncologist. 2014;19(8):851\u20139.","journal-title":"Oncologist."},{"key":"639_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S1470-2045(12)70584-3","volume":"14","author":"P Kapur","year":"2013","unstructured":"Kapur P, Pena-Llopis S, Christie A, et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol. 2013;14:159\u201367.","journal-title":"Lancet Oncol"},{"key":"639_CR37","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nature09639","volume":"469","author":"I Varela","year":"2011","unstructured":"Varela I, Tarpey P, Raine K, et al. Exome sequencing identifies frequent mutation of the SWI\/SNF complex gene PBRM1 in renal carcinoma. Nature. 2011;469:539\u201342.","journal-title":"Nature"},{"key":"639_CR38","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1158\/1078-0432.CCR-12-3886","volume":"19","author":"AA Hakimi","year":"2013","unstructured":"Hakimi AA, Ostrovnaya I, Reva B, et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res. 2013;19:3259\u201367.","journal-title":"Clin Cancer Res"},{"key":"639_CR39","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.eururo.2014.10.036","volume":"67","author":"EA Klein","year":"2015","unstructured":"Klein EA, Yousefi K, Haddad Z, et al. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. Eur Urol. 2015;67:778\u201386.","journal-title":"Eur Urol"},{"key":"639_CR40","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","volume":"373","author":"JA Sparano","year":"2015","unstructured":"Sparano JA, Gray RJ, Makower DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 2015;373:2005\u201314.","journal-title":"N Engl J Med"},{"key":"639_CR41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.eururo.2014.02.035","volume":"66","author":"SA Brooks","year":"2014","unstructured":"Brooks SA, Brannon AR, Parker JS, et al. ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol. 2014;66:77\u201384.","journal-title":"Eur Urol"},{"key":"639_CR42","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/S1470-2045(15)70167-1","volume":"16","author":"B Rini","year":"2015","unstructured":"Rini B, Goddard A, Knezevic D, et al. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. Lancet Oncol. 2015;16:676\u201385.","journal-title":"Lancet Oncol"},{"key":"639_CR43","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1158\/1078-0432.CCR-18-0323","volume":"24","author":"BI Rini","year":"2018","unstructured":"\u2022 Rini BI, Escudier B, Martini JF, et al. Validation of the 16-gene recurrence score in patients with locoregional, high-risk renal cell carcinoma from a phase III trial of adjuvant sunitinib. Clin Cancer Res. 2018;24:4407\u201315. Analysis validating the 16-gene recurrence score prognostic value in patients enrolled on the S-TRAC trial.","journal-title":"Clin Cancer Res"},{"key":"639_CR44","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.tcb.2017.11.008","volume":"28","author":"C Lin","year":"2018","unstructured":"Lin C, Yang L. Long noncoding RNA in cancer: wiring signaling circuitry. Trends Cell Biol. 2018;28:287\u2013301.","journal-title":"Trends Cell Biol"},{"key":"639_CR45","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.eururo.2018.07.032","volume":"74","author":"L Qu","year":"2018","unstructured":"Qu L, Wang ZL, Chen Q, et al. Prognostic value of a long non-coding RNA signature in localized clear cell renal cell carcinoma. Eur Urol. 2018;74:756\u201363.","journal-title":"Eur Urol"},{"key":"639_CR46","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.eururo.2017.12.002","volume":"73","author":"TM Morgan","year":"2018","unstructured":"Morgan TM, Mehra R, Tiemeny P, et al. A multigene signature based on cell cycle proliferation improves prediction of mortality within 5 yr of radical nephrectomy for renal cell carcinoma. Eur Urol. 2018;73:763\u20139.","journal-title":"Eur Urol"},{"key":"639_CR47","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1001\/jamaoncol.2017.0076","volume":"3","author":"NB Haas","year":"2017","unstructured":"\u2022 Haas NB, Manola J, Dutcher JP, et al. Adjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE randomized trial. JAMA Oncol. 2017;3:1249\u201352 Subanalyses of the ASSURE trial continued to show no disease free or overall survival benefit in subsets of patients with high risk diesase by stage, clear cell disease or by dose intensity of the TKI.","journal-title":"JAMA Oncol"},{"key":"639_CR48","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.eururo.2017.09.008","volume":"73","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Ravaud A, Patard JJ, et al. Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results. Eur Urol. 2018;73:62\u20138.","journal-title":"Eur Urol"},{"key":"639_CR49","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1093\/annonc\/mdy329","volume":"29","author":"M Staehler","year":"2018","unstructured":"Staehler M, Motzer RJ, George DJ, et al. Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial. Ann Oncol. 2018;29:2098\u2013104.","journal-title":"Ann Oncol"},{"key":"639_CR50","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1158\/1078-0432.CCR-17-2822","volume":"24","author":"DJ George","year":"2018","unstructured":"George DJ, Martini JF, Staehler M, et al. Immune biomarkers predictive for disease-free survival with adjuvant sunitinib in high-risk locoregional renal cell carcinoma: from randomized phase III S-TRAC study. Clin Cancer Res. 2018;24:1554\u201361.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"639_CR51","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.eururo.2016.11.034","volume":"71","author":"A Bex","year":"2017","unstructured":"\u2022 Bex A, Albiges L, Ljungberg B, et al. Updated European Association of Urology guidelines regarding adjuvant therapy for renal cell carcinoma. Eur Urol. 2017;71(5):719\u201322 Metaanalysis and guidelines from a panel of European Association of Urology comprised of kidney cancer experts and patient representatives which did not recommend the adjuvant administration of sunitinib.","journal-title":"Eur Urol"},{"key":"639_CR52","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.eururo.2018.05.002","volume":"74","author":"M Sun","year":"2018","unstructured":"Sun M, Marconi L, Eisen T, et al. Adjuvant vascular endothelial growth factor-targeted therapy in renal cell carcinoma: a systematic review and pooled analysis. Eur Urol. 2018;74:611\u201320.","journal-title":"Eur Urol"},{"key":"639_CR53","first-page":"802","volume":"9","author":"MH Bui","year":"2003","unstructured":"Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9:802\u201311.","journal-title":"Clin Cancer Res"},{"key":"639_CR54","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/jamaoncol.2016.4419","volume":"3","author":"K Chamie","year":"2017","unstructured":"Chamie K, Donin NM, Klopfer P, et al. Adjuvant weekly girentuximab following nephrectomy for high-risk renal cell carcinoma: the ARISER randomized clinical trial. JAMA Oncol. 2017;3:913\u201320.","journal-title":"JAMA Oncol"},{"issue":"15_suppl","key":"639_CR55","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.1200\/JCO.2018.36.15_suppl.4502","volume":"36","author":"Giuseppe Procopio","year":"2018","unstructured":"Procopio G, Cognetti F, Miceli R, et al. A randomized, open label, multicenter phase 2 study, to evaluate the efficacy of sorafenib (So) in patients (pts) with metastatic renal cell carcinoma (mRCC) after a radical resection of metastases: RESORT trial. J Clin Oncol. 2018;36, no. 15_suppl 4502\u20134502.","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"639_CR56","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.eururo.2016.11.020","volume":"71","author":"S Fern\u00e1ndez-Pello","year":"2017","unstructured":"Fern\u00e1ndez-Pello S, Hofmann F, Tahbaz R, et al. A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma. Eur Urol. 2017;71(3):426\u201336.","journal-title":"Eur Urol"},{"key":"639_CR57","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","volume":"66","author":"BE Houk","year":"2010","unstructured":"Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol. 2010;66:357\u201371.","journal-title":"Cancer Chemother Pharmacol"},{"key":"639_CR58","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/jcph.73","volume":"53","author":"BI Rini","year":"2013","unstructured":"Rini BI, Garrett M, Poland B, Dutcher JP, Rixe O, Wilding G, et al. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. J Clin Pharmacol. 2013;53:491\u2013504.","journal-title":"J Clin Pharmacol"},{"key":"639_CR59","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1093\/annonc\/mdv103","volume":"26","author":"BI Rini","year":"2015","unstructured":"Rini BI, Melichar B, Fishman MN, Oya M, Pithavala YK, Chen Y, et al. Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma. Ann Oncol. 2015;26:1372\u20137.","journal-title":"Ann Oncol"},{"key":"639_CR60","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1038\/bjc.2014.503","volume":"111","author":"AB Suttle","year":"2014","unstructured":"Suttle AB, Ball HA, Molimard M, Hutson TE, Carpenter C, Rajagopalan D, et al. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer. 2014;111:1909\u201316.","journal-title":"Br J Cancer"},{"key":"639_CR61","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-17-2652","volume":"24","author":"CN Sternberg","year":"2018","unstructured":"\u2022 Sternberg CN, Donskov F, Haas NB, et al. Pazopanib exposure relationship with clinical efficacy and safety in the adjuvant treatment of advanced renal cell carcinoma. Clin Cancer Res. 2018;24:3005\u201313 Study demonstrating that higher pazopanib exposure was associated with improved efficacy in patients who received adjuvant pazopanib on the PROTECT trial.","journal-title":"Clin Cancer Res"},{"key":"639_CR62","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative G","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative G. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386:1341\u201352.","journal-title":"Lancet"},{"issue":"29","key":"639_CR63","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1200\/JCO.2006.10.4323","volume":"25","author":"DJ Sargent","year":"2007","unstructured":"Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT group. J Clin Oncol. 2007;25(29):4569\u201374.","journal-title":"J Clin Oncol"},{"issue":"Issue suppl_8","key":"639_CR64","first-page":"2018","volume":"29","author":"DJ George","year":"2018","unstructured":"George DJ, Pantuck AJ, Figlin RA, et al. Correlations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: results from S-TRAC trial. Ann Oncol. 2018;29(Issue suppl_8):2018.","journal-title":"Ann Oncol"},{"key":"639_CR65","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"AM Eggermont","year":"2015","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522\u201330.","journal-title":"Lancet Oncol"},{"key":"639_CR66","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824\u201335.","journal-title":"N Engl J Med"},{"key":"639_CR67","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","volume":"6","author":"J Liu","year":"2016","unstructured":"\u2022 Liu J, Blake SJ, Yong MC, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016;6:1382\u201399. Preclinical data showing greater therapeutic efficacy of neoadjuvant PD-1 based immunotherapies compared to adjuvant administration.","journal-title":"Cancer Discov"},{"issue":"34","key":"639_CR68","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1200\/JCO.18.01148","volume":"36","author":"Andrea Necchi","year":"2018","unstructured":"Necchi A, Anichini A, Raggi D, et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J Clin Oncol. 2018:JCO1801148. \n                      https:\/\/doi.org\/10.1200\/JCO.18.01148\n                      \n                     [Epub ahead of print].","journal-title":"Journal of Clinical Oncology"},{"issue":"15_suppl","key":"639_CR69","doi-asserted-by":"publisher","first-page":"4506\u20134506","DOI":"10.1200\/JCO.2018.36.15_suppl.4506","volume":"36","author":"T Powles","year":"2018","unstructured":"Powles T, Rodriguez-Vida A, Duran I, et al. A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS). J Clin Oncol. 2018;36(15_suppl):4506\u20134506.","journal-title":"J Clin Oncol"},{"key":"639_CR70","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1200\/JCO.2017.35.15_suppl.506","volume":"35","author":"R Nanda","year":"2017","unstructured":"Nanda R, Liu MC, Yau C, et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2. J Clin Oncol. 2017;35(suppl 15) abstr 506:506.","journal-title":"J Clin Oncol"},{"issue":"21","key":"639_CR71","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378(21):1976\u201386.","journal-title":"N Engl J Med"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-019-0639-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-019-0639-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-019-0639-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T23:12:34Z","timestamp":1588374754000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-019-0639-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["639"],"URL":"https:\/\/doi.org\/10.1007\/s11864-019-0639-0","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"3 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Nieves Martinez Chanza has received compensation from Bayer for participation on advisory boards and has received reimbursement for travel expenses from Pfizer.Abhishek Tripathi declares that he has no conflict of interest.Lauren C. Harshman has received research funding (paid to her institution) from Bayer, Sotio, Bristol-Myers Squibb, Merck, Takeda, Dendreon\/Valeant, Janssen, Medivation\/Astellas, Genentech, and Pfizer; has received compensation for participation on advisory boards from Bayer, Genentech, Dendreon, Pfizer, Medivation\/Astellas, Merck, Exelixis, Corvus, Novartis, EMD Serono and Jounce Therapeutics; and has received reimbursement for travel expenses from Bayer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"44"}}